NovaBridge Biosciences(NBP)Earnings, Financials & Key Ratios
NBP•NASDAQ
$2.25
$422M mkt cap·Price updated May 6, 2026
AboutNovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.Show more
- Revenue$0-100.0%
- EBITDA-$373M+26.5%
- Net Income-$162M+88.9%
- EPS (Diluted)-4.46+74.7%
- ROE-16.91%+72.7%
- Debt/Equity0.02-75.2%
NBP Key Insights
NovaBridge Biosciences (NBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Share count reduced 2.5% through buybacks
✗Weaknesses
- ✗Weak momentum: RS Rating 8 (bottom 8%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
NBP Price & Volume
NovaBridge Biosciences (NBP) stock price & volume — 10-year historical chart
Loading chart...
NBP Growth Metrics
NovaBridge Biosciences (NBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM92.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM89.41%
Return on Capital
10 Years-31.1%
5 Years-18.42%
3 Years-19.37%
Last Year-31.21%
NBP Recent Earnings
NovaBridge Biosciences (NBP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (40%)
Q2 2026Latest
Apr 7, 2026EPS
$0.03
Est $0.01
-528.1%
Revenue
—
Q2 2026
Apr 2, 2026EPS
$0.03
Est $0.01
-529.0%
Revenue
—
Q4 2025
Dec 18, 2025EPS
$0.25
Est $0.01
-1801.1%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.01
Est $0.04
+76.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 7, 2026 | $0.03vs $0.01-528.1% | — |
| Q2 2026 | Apr 2, 2026 | $0.03vs $0.01-529.0% | — |
| Q4 2025 | Dec 18, 2025 | $0.25vs $0.01-1801.1% | — |
| Q4 2025 | Nov 12, 2025 | $0.01vs $0.04+76.5% | — |
Based on last 12 quarters of dataView full earnings history →
NBP Peer Comparison
NovaBridge Biosciences (NBP) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 VERA | 2.62B | 36.60 | -7.85 | -59.72% | 0.13 | |||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 |
Compare NBP vs Peers
NovaBridge Biosciences (NBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NBP Income Statement
NovaBridge Biosciences (NBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 11.56M | 53.78M | 30M | 1.54B | 88.03M | -10.7M | 4.49M | 0 | 0 |
| Revenue Growth % | - | 365.39% | -44.22% | 5042.23% | -94.29% | -112.15% | 141.93% | -100% | -100% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 46.43M | 27.24M | 0 | 0 | 216.28K |
| COGS % of Revenue | - | - | - | - | 52.75% | -254.62% | - | - | - |
| Gross Profit | 11.56M▲ 0% | 53.78M▲ 365.4% | 30M▼ 44.2% | 1.54B▲ 5042.2% | 41.59M▼ 97.3% | -248.8M▼ 698.2% | 4.49M▲ 101.8% | 0▼ 100.0% | -216.28K▲ 0% |
| Gross Margin % | 100% | 100% | 100% | 100% | 47.25% | 2325.83% | 100% | - | - |
| Gross Profit Growth % | - | 365.39% | -44.22% | 5042.23% | -97.3% | -698.16% | 101.8% | -100% | - |
| Operating Expenses | 310.58M | 461.42M | 1.51B | 1.39B | 2.11B | 355.38M | 515.65M | 375.36M | 34.74M |
| OpEx % of Revenue | 2687.63% | 857.95% | 5031.76% | 89.92% | 2400.31% | -3322.17% | 11495.09% | - | - |
| Selling, General & Admin | 25.44M | 66.39M | 654.55M | 402.41M | 899.94M | 199.88M | 63.91M | 216.46M | 21.46M |
| SG&A % of Revenue | 220.11% | 123.45% | 2181.84% | 26.09% | 1022.36% | -1868.47% | 1424.67% | - | - |
| Research & Development | 267.07M | 426.03M | 840.41M | 984.69M | 190.29M | 155.51M | 114.36M | 158.9M | 13.28M |
| R&D % of Revenue | 2311.14% | 792.15% | 2801.38% | 63.83% | 216.18% | -1453.7% | 2549.35% | - | - |
| Other Operating Expenses | 0 | 0 | 14.56M | 0 | 1.02B | -247 | 337.38M | 0 | 0 |
| Operating Income | -280.95M▲ 0% | -438.64M▼ 56.1% | -1.46B▼ 234.0% | 155.57M▲ 110.6% | -2.07B▼ 1431.4% | -366.08M▲ 82.3% | -511.16M▼ 39.6% | -375.36M▲ 26.6% | -34.74M▲ 0% |
| Operating Margin % | -2431.25% | -815.6% | -4883.23% | 10.08% | -2353.06% | 3422.17% | -11395.09% | - | - |
| Operating Income Growth % | - | -56.12% | -233.98% | 110.62% | -1431.43% | 82.33% | -39.63% | 26.57% | - |
| EBITDA | -279.32M | -431.9M | -1.46B | 168.31M | -2.06B | -364.66M | -507.79M | -373.45M | -33.25M |
| EBITDA Margin % | -2417.11% | -803.07% | -4850.46% | 10.91% | -2337.41% | 3408.94% | -11319.94% | - | - |
| EBITDA Growth % | - | -54.62% | -236.92% | 111.57% | -1322.44% | 82.28% | -39.25% | 26.46% | 87.64% |
| D&A (Non-Cash Add-back) | 1.63M | 6.74M | 9.83M | 12.74M | 13.78M | 1.42M | 3.37M | 1.91M | 216K |
| EBIT | -44.82M | -56.61M | -207.09M | 155.57M | -2.07B | -52.65M | -347.62M | -375.36M | -33.47M |
| Net Interest Income | -732.92K | -1.03M | 3.94M | 3.56M | 21.33M | 4.95M | 7.2M | 54.64M | 8.02M |
| Interest Income | 131.42K | 668.26K | 4.37M | 3.71M | 21.33M | 4.95M | 7.3M | 54.64M | 8.02M |
| Interest Expense | 864.34K | 1.7M | 427.48K | 146.48K | 0 | 0 | 101.85K | 0 | 0 |
| Other Income/Expense | -17.29M | 37.53M | 13.02M | 327.58M | -260.73M | -607.09M | -954.53M | 12.63M | 8.41M |
| Pretax Income | -298.24M▲ 0% | -401.11M▼ 34.5% | -1.45B▼ 262.0% | 483.15M▲ 133.3% | -2.33B▼ 582.7% | -973.17M▲ 58.3% | -1.47B▼ 50.6% | -362.73M▲ 75.3% | -26.33M▲ 0% |
| Pretax Margin % | -2580.82% | -745.82% | -4839.83% | 31.32% | -2649.26% | 9097.35% | -32674.02% | - | - |
| Income Tax | 0 | 1.72M | 0 | 12.23M | -494.81K | 697K | -1.26B | 0 | 0 |
| Effective Tax Rate % | 0% | -0.43% | 0% | 2.53% | 0.02% | -0.07% | 85.89% | 0% | 0% |
| Net Income | -298.24M▲ 0% | -402.83M▼ 35.1% | -1.49B▼ 268.6% | 470.92M▲ 131.7% | -2.33B▼ 595.1% | -2.51B▼ 7.5% | -1.47B▲ 41.5% | -162.26M▲ 88.9% | -24.54M▲ 0% |
| Net Margin % | -2580.82% | -749.02% | -4950% | 30.53% | -2648.7% | 23438.9% | -32674.02% | - | - |
| Net Income Growth % | - | -35.07% | -268.64% | 131.71% | -595.11% | -7.54% | 41.54% | 88.93% | 92.35% |
| Net Income (Continuing) | -45.68M | -58.56M | -207.52M | 470.92M | -2.33B | -2.51B | -206.77M | -362.73M | -26.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 200.47M | 1000K |
| Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.13▲ 0% | -6.92▼ 34.9% | -25.53▼ 268.9% | 6.90▲ 127.0% | -30.68▼ 544.6% | -30.38▲ 1.0% | -17.62▲ 42.0% | -4.46▲ 74.7% | -0.24▲ 0% |
| EPS Growth % | - | -34.89% | -268.93% | 127.03% | -544.64% | 0.98% | 42% | 74.69% | 89.41% |
| EPS (Basic) | -5.13 | -6.92 | -25.53 | 8.07 | -30.70 | -30.38 | -17.62 | -4.46 | - |
| Diluted Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.36M | 75.96M | 82.52M | 83.23M | 81.19M | 100.95M |
| Basic Shares Outstanding | 58.17M | 58.17M | 58.17M | 68.25M | 75.93M | 82.52M | 83.19M | 81.19M | 100.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NBP Balance Sheet
NovaBridge Biosciences (NBP) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 691.59M | 2.04B | 1.36B | 5.34B | 4.78B | 3.63B | 2.34B | 176.69M | 232.78M |
| Cash & Short-Term Investments | 574.17M | 1.84B | 1.17B | 733.21M | 670.96M | 3.45B | 2.29B | 173.4M | 228.27M |
| Cash Only | 307.93M | 1.59B | 1.14B | 4.76B | 3.52B | 3.21B | 2.14B | 68.26M | 228.06M |
| Short-Term Investments | 266.25M | 255.96M | 32M | 31.53M | 753.16M | 235.43M | 20.22M | 105.14M | 210K |
| Accounts Receivable | 628.15K | 9.36M | 7.99M | 71.31M | 60.95M | 4.81M | 1.83M | 1.17M | 926K |
| Days Sales Outstanding | 19.84 | 63.55 | 97.15 | 16.87 | 252.74 | -164.17 | 149.15 | - | - |
| Inventory | 0 | -215.57M | -55.87M | 0 | 4.27M | -80.28M | 28.95M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | 33.59 | - | - | - | - |
| Other Current Assets | 114.86M | 218.85M | 238.85M | 4.53B | 4.03B | 242.96M | 15.68M | 0 | 0 |
| Total Non-Current Assets | 333.75M | 339.08M | 376.25M | 990.13M | 847.71M | 447.19M | 276.3M | 35.99M | 44.63M |
| Property, Plant & Equipment | 22.34M | 27.66M | 46.5M | 40.27M | 158.5M | 123.97M | 5.55M | 3.8M | 3.17M |
| Fixed Asset Turnover | 0.52x | 1.94x | 0.65x | 38.31x | 0.56x | -0.09x | 0.81x | - | 0.00x |
| Goodwill | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 162.57M | 0 | 0 | 0 |
| Intangible Assets | 148.84M | 148.84M | 148.84M | 120.44M | 119.67M | 118.89M | 16.66M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 664.83M | 380.34M | 30.85M | 1.69M | 30.82M | 136.44M |
| Other Non-Current Assets | 0 | 0 | 18.33M | 2.01M | 26.63M | 10.91M | 252.39M | 1.36M | 5.02M |
| Total Assets | 1.03B▲ 0% | 2.38B▲ 131.7% | 1.74B▼ 26.9% | 6.33B▲ 264.5% | 5.63B▼ 11.1% | 4.07B▼ 27.6% | 2.61B▼ 35.9% | 212.68M▼ 91.9% | 277.41M▲ 0% |
| Asset Turnover | 0.01x | 0.02x | 0.02x | 0.24x | 0.02x | -0.00x | 0.00x | - | 0.00x |
| Asset Growth % | - | 131.72% | -26.87% | 264.52% | -11.12% | -27.64% | -35.86% | -91.86% | -91.2% |
| Total Current Liabilities | 195.14M | 346.16M | 588.48M | 576.13M | 624M | 659.74M | 411.81M | 8.45M | 16.09M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 99M | 80M | 50M | -34.8M | 0 | 2.75M | 29.97M | 0 | 872K |
| Deferred Revenue (Current) | 15.8M | 14.15M | 3.92M | 9.93M | 2.37M | 2.19M | 1.58M | 106K | 106K |
| Other Current Liabilities | 67.33M | 195.74M | 281.28M | 507.51M | -3.45M | 549.85M | -1.12M | 0 | -872K |
| Current Ratio | 3.54x | 5.88x | 2.31x | 9.28x | 7.66x | 5.50x | 5.67x | 20.90x | 20.90x |
| Quick Ratio | 3.54x | 6.51x | 2.41x | 9.28x | 7.66x | 5.62x | 5.60x | 20.90x | 20.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.13B | 2.98B | 3.18B | 130.52M | 417.63M | 405.6M | 483M | 3.07M | 2.4M |
| Long-Term Debt | 114.01M | 67.03M | 68.2M | 5.54M | 112.45M | 0 | 58.91M | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 7.49M | 5.54M | 81.79M | 32.07M | 23.1M | 3.07M | 10.95M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -8.97M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.02B | 2.92B | 3.11B | 119.44M | -610K | 373.53M | 400.99M | 520 | 0 |
| Total Liabilities | 1.33B | 3.33B | 3.77B | 706.65M | 1.04B | 1.07B | 894.81M | 11.52M | 18.5M |
| Total Debt | 213.01M | 147.03M | 132.5M | 13.6M | 112.45M | 38.29M | 133.87M | 3.88M | 3.27M |
| Net Debt | -94.92M | -1.44B | -1B | -4.75B | -3.41B | -3.18B | -2.01B | -64.38M | -224.79M |
| Debt / Equity | 36.02x | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x | 0.02x |
| Debt / EBITDA | - | - | - | 0.08x | - | - | - | - | -0.10x |
| Net Debt / EBITDA | - | - | - | -28.19x | - | - | - | - | 6.76x |
| Interest Coverage | -325.05x | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - | - |
| Total Equity | 5.91M▲ 0% | -955.1M▼ 16252.6% | -2.03B▼ 113.0% | 5.63B▲ 376.6% | 4.59B▼ 18.5% | 3.01B▼ 34.4% | 1.72B▼ 42.9% | 201.16M▼ 88.3% | 258.92M▲ 0% |
| Equity Growth % | - | -16252.61% | -113.03% | 376.56% | -18.47% | -34.43% | -42.89% | -88.29% | -175% |
| Book Value per Share | 0.10 | -16.42 | -34.98 | 82.31 | 60.40 | 36.46 | 20.64 | 2.48 | 2.56 |
| Total Shareholders' Equity | -299.8M | -955.1M | -2.03B | 5.63B | 4.59B | 3.01B | 1.72B | 201.16M | 258.92M |
| Common Stock | 6K | 6K | 6K | 114K | 126K | 132K | 18.76K | 19K | 27K |
| Retained Earnings | -357.86M | -1.01B | -2.49B | -2.02B | -4.35B | -6.77B | -8.33B | -1.29B | -1.3B |
| Treasury Stock | -1K | -1K | 0 | 0 | 0 | -21.25M | -56.8M | -6.22M | -5.24M |
| Accumulated OCI | 5.69M | 59.38M | 70.13M | -50.79M | -186.51M | 216.72M | 39.77M | 33.38M | 42.89M |
| Minority Interest | 305.71M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NBP Cash Flow Statement
NovaBridge Biosciences (NBP) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -252.16M | -280.7M | -867.98M | 433.56M | -973.09M | -1.1B | -72.85M | -52.65M | -52.67M |
| Operating CF Margin % | -2182.04% | -521.94% | -2893.27% | 28.1% | -1105.46% | 10309.24% | -1624.1% | - | - |
| Operating CF Growth % | - | -11.32% | -209.22% | 149.95% | -324.44% | -13.33% | 93.39% | 27.73% | 0% |
| Net Income | -298.24M | -402.83M | -1.45B | 470.92M | -2.33B | -2.51B | -208.18M | -49.7M | -24.54M |
| Depreciation & Amortization | 1.63M | 6.74M | 15.63M | 23.14M | 34.14M | 63.82M | 1.06M | 978K | 216.28K |
| Stock-Based Compensation | 7.04M | 3.52M | 366.89M | 493.46M | 608.61M | 357.15M | 10.26M | -1.95M | 15.65M |
| Deferred Taxes | 8.53M | -75.03M | -6.39M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 3.83M | 38.97M | 23.04M | -313.31M | 321.18M | 431.48M | 161.2M | 809K | 88.09M |
| Working Capital Changes | 25.04M | 147.93M | 184.79M | -240.64M | 394.52M | 552.06M | -37.2M | -2.81M | 7.01M |
| Change in Receivables | 0 | -11M | 11M | -130.5M | 97.42M | 33.08M | 0 | 0 | -1.44M |
| Change in Inventory | 0 | 0 | 0 | 0 | -27.24M | 27.24M | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 107.85M | 0 | 0 | 0 | 0 |
| Cash from Investing | -157.66M | 9.5M | 212.46M | -201.9M | -727.21M | 458.38M | -107.63M | -135.97M | -50.62K |
| Capital Expenditures | -20.33M | -14.41M | -12.24M | -8.01M | -29.93M | -45.83M | -164.35K | -48K | 3 |
| CapEx % of Revenue | 175.9% | 26.79% | 40.8% | 0.52% | 34% | -428.43% | 3.66% | - | - |
| Acquisitions | 93.33M | 0 | -224.7M | -257.65M | -6M | 0 | 0 | 0 | -23 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -230.67M | 23.91M | 224.7M | 52M | 0 | 26K | -107.47M | 62K | 0 |
| Cash from Financing | 758.59M | 1.48B | 152.71M | 3.44B | 593.92M | 42.36M | -8.25M | -334.89K | 60.87M |
| Debt Issued (Net) | 111.31M | 59.7M | 0 | -7.65M | 0 | 2.75M | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 0 | -1000K | -1000K | -335K | 1000K |
| Dividends Paid | 0 | 0 | -5.28M | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -5.34M | 0 | -3.08M | -8.66M | -335K | 0 |
| Other Financing | 594.2M | 1.23B | 131.76M | 2.91B | 593.92M | 60.86M | 407.88K | 0 | -967.91K |
| Net Change in Cash | 348.63M▲ 0% | 1.27B▲ 263.8% | -487.65M▼ 138.5% | 3.57B▲ 831.2% | -1.24B▼ 134.6% | -212.86M▲ 82.8% | -151.58M▲ 28.8% | -233.76M▼ 54.2% | 62.66M▲ 0% |
| Free Cash Flow | -272.48M▲ 0% | -295.11M▼ 8.3% | -880.22M▼ 198.3% | 425.55M▲ 148.3% | -1B▼ 335.7% | -1.15B▼ 14.5% | -73.02M▲ 93.6% | -52.72M▲ 27.8% | 1.85M▲ 0% |
| FCF Margin % | -2357.94% | -548.73% | -2934.08% | 27.59% | -1139.46% | 10737.67% | -1627.76% | - | - |
| FCF Growth % | - | -8.31% | -198.27% | 148.35% | -335.7% | -14.52% | 93.64% | 27.8% | - |
| FCF per Share | -4.68 | -5.07 | -15.13 | 6.22 | -13.20 | -13.92 | -0.88 | -0.65 | -0.65 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x | -0.08x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 710.39K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 1.42M | 103K | 0 | 0 | 0 |
NBP Key Ratios
NovaBridge Biosciences (NBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | 26.22% | -45.65% | -66.02% | -62.02% | -16.91% | -9.48% |
| Return on Invested Capital (ROIC) | - | - | 13.23% | -150.93% | -54.41% | - | - | -29.43% |
| Gross Margin | 100% | 100% | 100% | 47.25% | 2325.83% | 100% | - | - |
| Net Margin | -749.02% | -4950% | 30.53% | -2648.7% | 23438.9% | -32674.02% | - | - |
| Debt / Equity | - | - | 0.00x | 0.02x | 0.01x | 0.08x | 0.02x | 0.02x |
| Interest Coverage | -258.01x | -3426.98x | 1062.06x | - | - | -5018.58x | - | - |
| FCF Conversion | 0.70x | 0.58x | 0.92x | 0.42x | 0.44x | 0.05x | 0.32x | -0.08x |
| Revenue Growth | 365.39% | -44.22% | 5042.23% | -94.29% | -112.15% | 141.93% | -100% | -100% |
NBP Frequently Asked Questions
NovaBridge Biosciences (NBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
NovaBridge Biosciences (NBP) saw revenue decline by 100.0% over the past year.
NovaBridge Biosciences (NBP) reported a net loss of $24.5M for fiscal year 2024.
Dividend & Returns
NovaBridge Biosciences (NBP) has a return on equity (ROE) of -16.9%. Negative ROE indicates the company is unprofitable.
NovaBridge Biosciences (NBP) generated $1.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More NBP
NovaBridge Biosciences (NBP) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates